The usage of Merk’s antiviral pill for the treatment of patients who are fighting mild to moderate Covid-19.
We have just authorised the first oral antiviral for #COVID19, Lagevrio (molnupiravir).— MHRAgovuk (@MHRAgovuk) November 4, 2021
This follows a rigorous review of its safety, quality and effectiveness.
Find out more: https://t.co/B9Lm4U0Xzp pic.twitter.com/q5LNpsl2zP
Health Minister Sajid Javaid said in a press release that
“Today is a historic day for our country, as the UK is now the first country in the world to approve an antiviral that can be taken at home for COVID-19.”
He further went on to say that this approval will prove to be a game-changing decision for people who are the most vulnerable and immunosuppressed because of this disease.
Molnupiravir slows down the onset of the disease by affecting the ability of the virus to replicate.
According to the testing process of MRHA, this drug is safe to use so that the risk of general people’s hospitalization due to this drug can be minimized. Furthermore, it is also highly impressive in reducing the progression of disease from its mild form to severe form.
The effectiveness of this drug has been proved when it was taken at the earlier stage of the disease. The MHRA recommends that this drug should be used by people within five days of disease onset.
UK has ordered a bulk of 480,000 doses of Molnupiravir from US Pharma Giant Merck. If this drug gets approved by authorities then the US is planning to place an order of 1.7 million doses.